M
Michael P. La Quaglia
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 108
Citations - 4303
Michael P. La Quaglia is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Sarcoma & Survival rate. The author has an hindex of 32, co-authored 105 publications receiving 3533 citations. Previous affiliations of Michael P. La Quaglia include Harvard University & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino,Ayuko Hoshino,Han Sang Kim,Han Sang Kim,Linda Bojmar,Linda Bojmar,Linda Bojmar,Kofi Ennu Gyan,Michele Cioffi,Jonathan M. Hernandez,Jonathan M. Hernandez,Jonathan M. Hernandez,Constantinos P. Zambirinis,Constantinos P. Zambirinis,Gonçalo Rodrigues,Gonçalo Rodrigues,Henrik Molina,Søren Heissel,Milica Tesic Mark,Loïc Steiner,Loïc Steiner,Alberto Benito-Martin,Serena Lucotti,Angela Di Giannatale,Katharine Offer,Miho Nakajima,Caitlin Williams,Laura Nogués,Laura Nogués,Fanny A. Pelissier Vatter,Ayako Hashimoto,Ayako Hashimoto,Ayako Hashimoto,Alexander E. Davies,Daniela Freitas,Daniela Freitas,Candia M. Kenific,Yonathan Ararso,Weston Buehring,Pernille Lauritzen,Yusuke Ogitani,Kei Sugiura,Kei Sugiura,Naoko Takahashi,Maša Alečković,Kayleen A. Bailey,Joshua S. Jolissant,Joshua S. Jolissant,Huajuan Wang,Ashton Harris,L. Miles Schaeffer,Guillermo García-Santos,Guillermo García-Santos,Zoe Posner,Vinod P. Balachandran,Yasmin Khakoo,G. Praveen Raju,Avigdor Scherz,Irit Sagi,Ruth Scherz-Shouval,Yosef Yarden,Moshe Oren,Mahathi Malladi,Mary Petriccione,Kevin C. De Braganca,Maria Donzelli,Cheryl Fischer,Stephanie Vitolano,Geraldine P. Wright,Lee Ganshaw,Mariel Marrano,Amina Ahmed,Joe DeStefano,Enrico Danzer,Michael H.A. Roehrl,Norman J. Lacayo,Theresa C. Vincent,Theresa C. Vincent,Martin R. Weiser,Mary S. Brady,Paul A. Meyers,Leonard H. Wexler,Srikanth R. Ambati,Alexander J. Chou,Emily K. Slotkin,Shakeel Modak,Stephen S. Roberts,Ellen M. Basu,Daniel Diolaiti,Benjamin A. Krantz,Benjamin A. Krantz,Fatima Cardoso,Amber L. Simpson,Michael F. Berger,Charles M. Rudin,Diane M. Simeone,Maneesh Jain,Cyrus M. Ghajar,Surinder K. Batra,Ben Z. Stanger,Jack D. Bui,Kristy A. Brown,Vinagolu K. Rajasekhar,John H. Healey,Maria de Sousa,Maria de Sousa,Kim Kramer,Sujit Sheth,Jeanine Baisch,Virginia Pascual,Todd E. Heaton,Michael P. La Quaglia,David J. Pisapia,Robert E. Schwartz,Haiying Zhang,Yuan Liu,Arti Shukla,Laurence Blavier,Yves A. DeClerck,Mark A. LaBarge,Mina J. Bissell,Thomas C. Caffrey,Paul M. Grandgenett,Michael A. Hollingsworth,Jacqueline Bromberg,Jacqueline Bromberg,Bruno Costa-Silva,Héctor Peinado,Yibin Kang,Benjamin A. Garcia,Eileen M. O'Reilly,David P. Kelsen,Tanya M. Trippett,David R. Jones,Irina Matei,William R. Jarnagin,David Lyden +136 more
TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.
Journal ArticleDOI
Results of multimodal treatment for desmoplastic small round cell tumors.
TL;DR: Multimodal therapy results in improved survival in patients with DSRCT and Aggressive surgical resection of these extensive intraabdominal neoplasms correlates with improved patient outcome.
Journal ArticleDOI
Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.
Kurt D. Newman,Thomas J. Black,Glenn Heller,Richard G. Azizkhan,George Holcomb,Charles A. Sklar,Vaia Vlamis,Gerald M. Haase,Michael P. La Quaglia +8 more
TL;DR: Thyroid lobectomy alone may be appropriate for patients with small localized lesions while total or subtotal thyroidectomy should be considered for more extensive tumors, which suggests that biologic rather than treatment factors have a greater effect on outcome.
Journal Article
Hybrid Polar Histone Deacetylase Inhibitor Induces Apoptosis and CD95/CD95 Ligand Expression in Human Neuroblastoma
Richard D. Glick,Steven L. Swendeman,Dennis C. Coffey,Richard A. Rifkind,Paul A. Marks,Victoria M. Richon,Michael P. La Quaglia +6 more
TL;DR: The effect of CBHA on human neuroblastoma cells suggests that this agent and structurally related synthetic hybrid polar compounds have therapeutic potential for the treatment of this malignancy.
Journal Article
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
Dennis C. Coffey,Martha C. Kutko,Richard D. Glick,Lisa M. Butler,Glenn Heller,Richard A. Rifkind,Paul A. Marks,Victoria M. Richon,Michael P. La Quaglia +8 more
TL;DR: The results suggest HDACIs alone or combined with retinoids may have therapeutic utility for neuroblastoma.